title: UCF-101 mitigates streptozotocin-induced cardiomyocyte dysfunction: role of AMPK.
abstract: Diabetic heart disease contributes to the high mortality in diabetics, although effective clinical management is lacking. The protease inhibitor 5-[5-(2-nitrophenyl) furfuryliodine]-1,3-diphenyl-2-thiobarbituric acid (UCF-101) was reported to protect the hearts against ischemic injury. This study examined the role of UCF-101 on streptozotocin (STZ)-induced diabetic heart defect. Vehicle or UCF-101 was administrated to STZ diabetic mice, and cardiomyocyte mechanical properties were analyzed. UCF-101 reduced STZ-induced hyperglycemia and alleviated STZ-induced aberration in cardiomyocyte contractile mechanics. Diabetes dramatically decreased AMPK phosphorylation at Thr(172) of catalytic alpha-subunit, which was restored by UCF-101. Neither diabetes nor UCF-101 affected the expression of HtrA2/Omi and XIAP or caspase-3 activity. The AMPK activator resveratrol mimicked the UCF-101-induced beneficial effect against diabetic cardiac dysfunction. Mechanical properties in cardiomyocytes from the AMPK-kinase-dead (KD) mice displayed markedly impaired contractile function reminiscent of diabetes. STZ injection in AMPK-KD mice failed to elicit any additional cardiomyocyte contractile defect. UCF-101 significantly downregulated the AMPK-degrading enzymes PP2A and PP2C, the effect of which was mimicked by resveratrol. Taken together, these results indicate that UCF-101 protects against STZ-induced cardiac dysfunction, possibly through AMPK signaling.
authors.affiliation: Division of Pharmaceutical Sciences, University of Wyoming, Laramie, WY 82071, USA.
authors.forename: Qun
authors.initials: Q
authors.lastname: Li
authors.forename: Ji
authors.initials: J
authors.lastname: Li
authors.forename: Jun
authors.initials: J
authors.lastname: Ren
mesh_terms: D000263:Adenylate Kinase / Q000378:metabolism*; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D001786:Blood Glucose / Q000378:metabolism; D015153:Blotting, Western; D053148:Caspase 3 / Q000378:metabolism; D002469:Cell Separation; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology*; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D007527:Isoenzymes / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009200:Myocardial Contraction / Q000187:drug effects; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000201:enzymology / Q000502:physiology*; D010766:Phosphorylation; D011480:Protease Inhibitors / Q000494:pharmacology*; D054648:Protein Phosphatase 2 / Q000378:metabolism; D011744:Pyrimidinones / Q000494:pharmacology*; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology; D013871:Thiones / Q000494:pharmacology*
chemical_list: D000975:Antioxidants; D001786:Blood Glucose; D007527:Isoenzymes; D011480:Protease Inhibitors; D011744:Pyrimidinones; D013267:Stilbenes; D013871:Thiones; C501517:UCF 101; D000263:Adenylate Kinase; D054648:Protein Phosphatase 2; D053148:Caspase 3; D000077185:Resveratrol
references.citation: Diabetes. 2005 Jan;54(1):63-8
references.pmid: 15616011
references.citation: Rejuvenation Res. 2007 Dec;10(4):501-12
references.pmid: 17979500
references.citation: Anal Biochem. 1976 May 7;72:248-54
references.pmid: 942051
references.citation: Circulation. 2008 Jan 22;117(3):440-9
references.pmid: 18212301
references.citation: Am J Physiol. 1997 Jan;272(1 Pt 2):H148-58
references.pmid: 9038933
references.citation: Eur J Pharmacol. 2007 Feb 28;557(2-3):168-77
references.pmid: 17182030
references.citation: Diabetes. 2003 Mar;52(3):777-83
references.pmid: 12606520
references.citation: Am J Physiol Endocrinol Metab. 2003 Feb;284(2):E366-76
references.pmid: 12531745
references.citation: Circulation. 2005 Jan 4;111(1):90-6
references.pmid: 15611365
references.citation: Neurochem Int. 2007 Jan;50(1):172-80
references.pmid: 16978742
references.citation: Am J Physiol Endocrinol Metab. 2002 Oct;283(4):E658-66
references.pmid: 12217882
references.citation: Cardiovasc Ther. 2008 Fall;26(3):224-32
references.pmid: 18786092
references.citation: Am J Physiol Heart Circ Physiol. 2006 Dec;291(6):H2557-69
references.pmid: 16844922
references.citation: Diabetes. 2006 Aug;55(8):2180-91
references.pmid: 16873680
references.citation: N Engl J Med. 2008 Feb 7;358(6):580-91
references.pmid: 18256393
references.citation: Aging Cell. 2007 Dec;6(6):799-806
references.pmid: 17973971
references.citation: Am J Physiol Heart Circ Physiol. 2000 Jul;279(1):H238-44
references.pmid: 10899062
references.citation: Exp Physiol. 2009 Sep;94(9):984-94
references.pmid: 19561140
references.citation: Am J Physiol Endocrinol Metab. 2005 Jan;288(1):E216-21
references.pmid: 15367397
references.citation: J Biol Chem. 2007 Mar 30;282(13):9777-9788
references.pmid: 17255104
references.citation: J Cell Mol Med. 2008 Dec;12(6A):2350-61
references.pmid: 18266981
references.citation: Am J Physiol. 1999 Aug;277(2):H643-9
references.pmid: 10444490
references.citation: J Biol Chem. 2003 Mar 28;278(13):11489-94
references.pmid: 12529364
references.citation: Am J Physiol Heart Circ Physiol. 2000 Oct;279(4):H1708-14
references.pmid: 11009458
references.citation: Mol Cell. 2001 May;7(5):1085-94
references.pmid: 11389854
references.citation: J Biol Chem. 2008 Aug 29;283(35):24194-201
references.pmid: 18562309
references.citation: J Clin Invest. 2004 Aug;114(4):495-503
references.pmid: 15314686
references.citation: Cell Metab. 2005 Jan;1(1):15-25
references.pmid: 16054041
references.citation: Circulation. 2009 Mar 31;119(12):1643-52
references.pmid: 19289642
references.citation: J Endocrinol. 2004 Jan;180(1):175-82
references.pmid: 14709156
references.citation: Biochem J. 2003 Oct 1;375(Pt 1):1-16
references.pmid: 12839490
references.citation: Cell Metab. 2006 Jun;3(6):403-16
references.pmid: 16753576
references.citation: Am J Cardiol. 1999 Jun 17;83(12A):25H-30H
references.pmid: 10750583